- Cellipont Bioservices has entered a strategic collaboration with Soter Bio to provide integrated RNA and cell therapy manufacturing services.
- The partnership combines GMP RNA production with GMP cell therapy contract manufacturing to streamline development timelines and reduce technical handoffs.
Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), has announced a strategic collaboration with Soter Bio, a CDMO specializing in RNA and RNA–lipid nanoparticle manufacturing for research and GMP applications. The companies will provide coordinated manufacturing pathways for cell therapy programs that require integrated biomolecule and cellular processing.
Under the agreement, Cellipont will deliver GMP cell therapy manufacturing, analytical development, and regulatory execution from early clinical stages through late-stage supply. Soter Bio will provide GMP RNA and biomolecule manufacturing to support upstream inputs for RNA-enabled cell engineering and next-generation therapeutic programs.
The collaboration is intended to help sponsors accelerate development timelines, reduce technical handoffs, and strengthen domestic manufacturing resilience. The companies stated that the integrated U.S.-based model reflects growing demand for end-to-end biomanufacturing platforms that span RNA production through cell processing.
“As cell therapies and RNA-enabled approaches become more technically integrated, early alignment across manufacturing stages is critical to de-risk development and move programs efficiently into the clinic.” Both companies will continue to operate independently while collaborating to support shared clients across biotechnology, pharmaceutical, and government-sponsored programs.
Darren Head, CEO of Cellipont
